Anocca raises SEK 440 million
Anocca AB has raised SEK 440 million ($46 million) from Mellby Gård, a Swedish investment group, and existing shareholders to conduct a programme of trials of T cell immunotherapies for pancreatic cancer. The trials will investigate multiple approaches for targeting mutations in the KRAS gene which is involved in the regulation of cell division. KRAS mutations are drivers of pancreatic cancer, as well as lung and colorectal cancers.